AU2018320419B2 - Morpholinylpyridone compounds - Google Patents

Morpholinylpyridone compounds Download PDF

Info

Publication number
AU2018320419B2
AU2018320419B2 AU2018320419A AU2018320419A AU2018320419B2 AU 2018320419 B2 AU2018320419 B2 AU 2018320419B2 AU 2018320419 A AU2018320419 A AU 2018320419A AU 2018320419 A AU2018320419 A AU 2018320419A AU 2018320419 B2 AU2018320419 B2 AU 2018320419B2
Authority
AU
Australia
Prior art keywords
trifluoromethyl
pharmaceutically acceptable
acceptable salt
compound according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018320419A
Other languages
English (en)
Other versions
AU2018320419A1 (en
Inventor
Rickard Forsblom
Johan LINDSTRÖM
Jenny Viklund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sprint Bioscience AB
Original Assignee
Sprint Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience AB filed Critical Sprint Bioscience AB
Publication of AU2018320419A1 publication Critical patent/AU2018320419A1/en
Application granted granted Critical
Publication of AU2018320419B2 publication Critical patent/AU2018320419B2/en
Priority to AU2023285995A priority Critical patent/AU2023285995A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018320419A 2017-08-23 2018-08-23 Morpholinylpyridone compounds Active AU2018320419B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023285995A AU2023285995A1 (en) 2017-08-23 2023-12-22 Morpholinylpyridone Compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
EP17187567.7 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023285995A Division AU2023285995A1 (en) 2017-08-23 2023-12-22 Morpholinylpyridone Compounds

Publications (2)

Publication Number Publication Date
AU2018320419A1 AU2018320419A1 (en) 2020-04-09
AU2018320419B2 true AU2018320419B2 (en) 2023-09-28

Family

ID=59686888

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018320419A Active AU2018320419B2 (en) 2017-08-23 2018-08-23 Morpholinylpyridone compounds
AU2023285995A Abandoned AU2023285995A1 (en) 2017-08-23 2023-12-22 Morpholinylpyridone Compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023285995A Abandoned AU2023285995A1 (en) 2017-08-23 2023-12-22 Morpholinylpyridone Compounds

Country Status (20)

Country Link
US (2) US11560374B2 (enExample)
EP (2) EP3672962B1 (enExample)
JP (2) JP7199736B2 (enExample)
KR (1) KR102732013B1 (enExample)
CN (3) CN116462674A (enExample)
AU (2) AU2018320419B2 (enExample)
CY (1) CY1125117T1 (enExample)
DK (1) DK3672962T3 (enExample)
ES (1) ES2910157T3 (enExample)
HR (1) HRP20220497T1 (enExample)
HU (1) HUE058661T2 (enExample)
IL (3) IL302077A (enExample)
LT (1) LT3672962T (enExample)
PL (1) PL3672962T3 (enExample)
PT (1) PT3672962T (enExample)
RS (1) RS63109B1 (enExample)
SI (1) SI3672962T1 (enExample)
SM (1) SMT202200169T1 (enExample)
TW (2) TW202348601A (enExample)
WO (1) WO2019038390A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12414955B2 (en) 2020-11-25 2025-09-16 Deciphera Pharmaceuticals, Llc Anti-viral activity of VPS34 inhibitors
CN117241800A (zh) * 2020-11-25 2023-12-15 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
JP2023550641A (ja) 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ，エルエルシー ウイルス感染症の治療に使用するためのｖｓｐ３４阻害剤としてのモルホリノ誘導体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
WO2013190510A2 (en) * 2012-06-22 2013-12-27 Sanofi NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
US8685993B2 (en) 2010-12-21 2014-04-01 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
EP3042900B1 (en) * 2013-08-29 2020-09-23 Fujifilm Corporation Novel morpholine derivative or salt thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MY182908A (en) 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
SI3416957T1 (sl) * 2016-02-19 2020-11-30 Sprint Bioscience Ab Spojine 6-heterociklil-4-morfolin-4-ilpiridin-2-ona, uporabne za zdravljenje raka in diabetesa
AU2017219846B2 (en) * 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
WO2013190510A2 (en) * 2012-06-22 2013-12-27 Sanofi NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF

Also Published As

Publication number Publication date
KR102732013B1 (ko) 2024-11-18
IL292489B1 (en) 2023-05-01
EP3672962B1 (en) 2022-01-26
CN111108102B (zh) 2023-04-28
EP4056569A1 (en) 2022-09-14
TW202348601A (zh) 2023-12-16
SI3672962T1 (sl) 2022-06-30
IL272815A (en) 2020-04-30
PT3672962T (pt) 2022-04-12
RU2020110506A (ru) 2021-09-23
US20200361922A1 (en) 2020-11-19
WO2019038390A1 (en) 2019-02-28
US20230234949A1 (en) 2023-07-27
SMT202200169T1 (it) 2022-05-12
CY1125117T1 (el) 2024-12-13
JP7199736B2 (ja) 2023-01-06
JP2020531485A (ja) 2020-11-05
EP3672962A1 (en) 2020-07-01
HUE058661T2 (hu) 2022-09-28
CN111108102A (zh) 2020-05-05
CA3073142A1 (en) 2019-02-28
CN116444510A (zh) 2023-07-18
US11560374B2 (en) 2023-01-24
ES2910157T3 (es) 2022-05-11
IL292489A (en) 2022-06-01
LT3672962T (lt) 2022-05-10
IL302077A (en) 2023-06-01
IL272815B (en) 2022-06-01
JP2023021268A (ja) 2023-02-10
RU2020110506A3 (enExample) 2022-02-22
KR20200044025A (ko) 2020-04-28
AU2018320419A1 (en) 2020-04-09
AU2023285995A1 (en) 2024-01-25
HRP20220497T1 (hr) 2022-05-27
PL3672962T3 (pl) 2022-05-02
TWI803511B (zh) 2023-06-01
RS63109B1 (sr) 2022-04-29
DK3672962T3 (da) 2022-05-02
CN116462674A (zh) 2023-07-21
TW201912161A (zh) 2019-04-01
IL292489B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2021215234B2 (en) 6-Aryl-4-Morpholin-1-Ylpyridone Compounds Useful For The Treatment Of Cancer And Diabetes
AU2018320418B2 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
AU2023285995A1 (en) Morpholinylpyridone Compounds
AU2023258375A1 (en) Pyridylpyridone Compounds
IL272792A (en) Azaindolylpyridone and diazaindolylpyridone compounds
CA3073142C (en) Morpholinylpyridone compounds
HK40079060A (en) Morpholinylpyridone compounds
RU2803158C2 (ru) Морфолинилпиридоны
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)